Archives of medical sciences. Atherosclerotic diseases最新文献

{"title":"Artificial intelligence in preventive care in primary health care settings: a scoping review.","authors":"Paraskevi F Katsakiori, Francesk Mulita, Panagiotis Papadimitroulas","doi":"10.5114/amsad/220788","DOIUrl":"10.5114/amsad/220788","url":null,"abstract":"<p><p>Artificial Intelligence (AI) could be integrated into Primary Health Care (PHC) to enhance the preventive care of several diseases. This scoping review aims to provide current evidence on AI applications for the prevention of non-infectious diseases in PHC. A structured search was conducted in PubMed/Medline and Scopus databases to identify studies evaluating AI-based interventions implemented in the preventive care of non-infectious diseases in the PHC sector. AI-supported preventive care was compared to standard preventive care or non-AI-based interventions. Preventive medicine was defined as at least one primary outcome related to disease incidence, risk reduction, and early detection rates of non-infectious diseases. AI demonstrates significant potential in preventive medicine in PHC as it enables proactive, personalized, and data-driven interventions. However, its adoption requires strategies to overcome technical, ethical, and organizational barriers. Future research should address real-world implementation, cost-effectiveness, and clinician engagement to maximize clinical impact.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e72-e77"},"PeriodicalIF":0.0,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of β-blocker therapy after acute myocardial infarction in patients with preserved ejection fraction: a meta-analysis.","authors":"Tony Chandy Babu, Hala Sharaf, Haniya Mallick, Omar Alzaabi, Moaz Alowami, Abdul Khan, Eman Ibrahim Elzain Hassan, Rajdeepsinh Hariharsinh Rana, Yasmeen Maarraoui, Mohammed Alrubaei, Zenab Ehsan, Eeshal Zulfiqar","doi":"10.5114/amsad/220339","DOIUrl":"10.5114/amsad/220339","url":null,"abstract":"<p><strong>Introduction: </strong>Despite earlier evidence, the benefit of long-term β-blockers after myocardial infarction (MI) in patients with preserved or mildly reduced ejection fraction remains unclear in the modern reperfusion era.</p><p><strong>Methods: </strong>We conducted a PRISMA-guided systematic review and meta-analysis by searching the PubMed, Google Scholar, and Cochrane databases, pooling results using a random effects model with 95% CIs.</p><p><strong>Results: </strong>Five RCTs, including a total of 23,524 participants, were analysed. B-blocker therapy showed no significant effect on all-cause mortality (RR = 0.98, 95% CI: 0.87-1.11) or cardiovascular mortality (RR = 1.06, 95% CI: 0.83-1.36). Similarly, no significant differences were observed for secondary outcomes: major adverse cardiovascular events (MACE) (RR = 0.96, 95% CI: 0.85-1.07), recurrent MI (RR = 0.89, 95% CI: 0.78-1.02), stroke (RR = 1.27, 95% CI: 0.92-1.76), or hospitalisations for HF (HF) (RR = 0.77, 95% CI: 0.56-1.05).</p><p><strong>Conclusions: </strong>Long-term β-blockers showed no reduction in mortality, recurrent MI, stroke, MACE, or HF admissions, indicating limited routine benefit.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e78-e86"},"PeriodicalIF":0.0,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Troubleshooting technique in endovascular abdominal aortic aneurysm repair with the ALTO endograft.","authors":"Spyros Papadoulas, Konstantinos Nikolakopoulos, Chrysanthi Papageorgopoulou, Kate Tabaku, Zois Sargentis, Aristidis Sarakinos, Francesk Mulita","doi":"10.5114/amsad/220355","DOIUrl":"10.5114/amsad/220355","url":null,"abstract":"","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e53-e58"},"PeriodicalIF":0.0,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A high-risk perioperative atrial fibrillation phenotype and early outcomes after isolated coronary artery bypass grafting.","authors":"Emced Khalil, Burak Yüksel","doi":"10.5114/amsad/220354","DOIUrl":"10.5114/amsad/220354","url":null,"abstract":"<p><strong>Introduction: </strong>Perioperative atrial fibrillation (POAF) remains the most common arrhythmic complication occurring in the setting of isolated coronary artery bypass grafting (CABG), and it is now being increasingly recognised as a marker of early postoperative morbidity, rather than a simple rhythm disturbance. The aim of the research to find the independent clinical and procedural predictors of POAF in patients with isolated CABG, as well as to assess the relationship with early clinically significant outcomes.</p><p><strong>Material and methods: </strong>In this single-centre retrospective cohort analysis, consecutive adult patients who received isolated CABG surgery between January 2022 and December 2025 were included. Patients with a history of atrial fibrillation/flutter, simultaneous cardiac surgery, and incomplete perioperative records were excluded. POAF was identified as new atrial fibrillation/flutter occurring within seven days of surgery or before discharge. Multivariate logistic regression analysis was used to evaluate independent predictors of POAF. Early postoperative outcomes were compared between patients with and without POAF.</p><p><strong>Results: </strong>In the study involving 550 patients, POAF occurred in 150 (27.3%) patients. Multivariate analysis showed that advanced age, chronic kidney disease, increased left atrial dimension, decreased left ventricular ejection fraction, prolonged cardiopulmonary bypass time, and perioperative red blood cell transfusion were significant predictors of POAF. Patients with POAF had increased rates of acute kidney injury (22.0% vs. 11.0%, <i>p</i> = 0.001), increased intensive care unit stay, and increased hospital stay, compared to those without POAF. There was no significant difference in in-hospital mortality.</p><p><strong>Conclusions: </strong>In the case of isolated CABG, the incidence of POAF is related to a higher incidence of early postoperative morbidity, but it is not related to in-hospital mortality. The identification of at-risk patients with the use of clinical data could contribute to the evaluation of risk stratification.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e59-e64"},"PeriodicalIF":0.0,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Planned first-line bilateral femoral access for endovascular treatment of unilateral common iliac artery chronic total occlusion: procedural control and outcomes.","authors":"Emced Khalil","doi":"10.5114/amsad/220353","DOIUrl":"10.5114/amsad/220353","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic total occlusion (CTO) of the common iliac artery (CIA) represents a technically challenging subset of aorto-iliac occlusive disease, particularly when the lesion extends close to the aorto-iliac bifurcation. Although endovascular therapy has become the preferred treatment modality, the optimal access strategy for unilateral CIA CTO remains uncertain. This study aimed to evaluate the feasibility, procedural control, and clinical outcomes of a planned first-line bilateral femoral access strategy in unilateral CIA CTO.</p><p><strong>Material and methods: </strong>This retrospective single-centre study included 30 consecutive patients with unilateral CIA CTO who underwent endovascular revascularisation using a first-line bilateral femoral approach between January 2020 and December 2024. Continuous contralateral diagnostic angiography was used to guide the lesion crossing and stent deployment. Lesions were classified according to the TransAtlantic Inter-Society Consensus (TASC II). Technical success was defined as residual stenosis < 30% with restoration of antegrade flow. Procedural complications and mid-term clinical outcomes were assessed.</p><p><strong>Results: </strong>Most lesions were classified as TASC II C-D (86.7%). Technical success was achieved in 93.3% of cases. Periprocedural complications were infrequent and included access-site haematoma (6.7%), flow-limiting dissection (3.3%), and distal embolisation (3.3%). During a median follow-up of 13 months, symptom recurrence occurred in 20.0% of patients. Imaging performed in symptomatic patients confirmed restenosis or reocclusion in 13.3%, and target lesion revascularisation was required in 10.0% of cases.</p><p><strong>Conclusions: </strong>A planned first-line bilateral femoral endovascular approach for unilateral CIA CTO is feasible and safe, achieving high technical success with low complication rates even in predominantly TASC II C-D lesions. By enhancing procedural control and bifurcation preservation, this strategy may be particularly valuable in anatomically complex cases.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e65-e71"},"PeriodicalIF":0.0,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of P2Y₁₂ inhibitors vs. aspirin monotherapy following dual antiplatelet therapy in patients after percutaneous coronary intervention: a systematic review and meta-analysis.","authors":"Muhammad Hazqeel Kazmi, Taha Kassim Dohadwala, Syed Mohammad Haleem, Umabalan Thirupathy, Piyush Sajnani, Pena Campos Indira Camila, Mennatalla Ayyad, Brandon Xian Ch'ng, Muhammad Muneeb Arshad, Ibrahim Ali Nasser, Ahmad Mesmar, Muhammad Nadeem Khawaja, Amer 'Mohammad Amin' Al-Zou'bi, Salman Chatha, Osama Tariq, Eeshal Zulfiqar, Mushood Ahmed, Raheel Ahmed","doi":"10.5114/amsad/216337","DOIUrl":"10.5114/amsad/216337","url":null,"abstract":"<p><strong>Introduction: </strong>P2Y₁₂ inhibitor monotherapy has emerged as a potential alternative to aspirin following dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI), but the optimal choice remains uncertain.</p><p><strong>Methods: </strong>A systematic literature search compared P2Y₁₂ inhibitors with aspirin post PCI. A random-effects model pooled odds ratios (ORs) with 95% confidence intervals (CIs) for outcomes.</p><p><strong>Results: </strong>Seven studies (29,756 patients) were included. P2Y₁₂ inhibitors significantly reduced MACE compared to aspirin [OR = 0.73; 95% CI: 0.64-0.84]. No significant difference was observed in all-cause mortality [OR = 0.90; 95% CI: 0.77-1.05], cardiac death [OR = 0.86; 95% CI: 0.68-1.09], major bleeding [OR = 1.06; 95% CI: 0.67-1.68], MI [OR = 0.78; 95% CI: 0.56-1.08], or stent thrombosis [OR = 0.71; 95% CI: 0.41-1.22]. P2Y₁₂ inhibitors significantly reduced repeat revascularisation [OR = 0.83; 95% CI: 0.73-0.94] and stroke [OR = 0.63; 95% CI: 0.48-0.81].</p><p><strong>Conclusions: </strong>P2Y₁₂ inhibitors may be a safer, more effective alternative to aspirin alone after PCI.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e24-e37"},"PeriodicalIF":0.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of torsemide versus furosemide in heart failure: a systematic review and meta-analysis of randomized controlled trials.","authors":"Mohamed Magdi Eid, Ahmed M Altibi, Mostafa Reda Mostafa, Andrew Takla, Ahmad Salem, Claudine Abdou, Majd Al Deen Alhuarrat, Devesh Rai, Wilbert S Aronow, Kirolos Barrsoum","doi":"10.5114/amsad/210582","DOIUrl":"10.5114/amsad/210582","url":null,"abstract":"<p><strong>Introduction: </strong>Loop diuretics are a cornerstone in the symptomatic management of heart failure. There is conflicting evidence regarding potential differences between torsemide and furosemide in their effects on heart failure outcomes. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to compare the therapeutic efficacy of furosemide versus torsemide in the management of heart failure.</p><p><strong>Methods: </strong>Medline/PubMed, Embase, and Cochrane Central Register of Controlled Trials were queried for studies comparing furosemide to torsemide in heart failure from inception to January 2023. Outcomes of interest included all-cause mortality, hospitalization due to heart failure, and weight change.</p><p><strong>Results: </strong>Our analysis included 10 RCTs comprising 4011 patients, of whom 2019 were treated with furosemide and 1992 patients were treated with torsemide. There was no significant difference between the groups in terms of all-cause mortality (OR = 0.99; 95% CI: 0.97-1.02; <i>p</i> = 0.66; <i>I</i> ² = 0.03%) or heart failure hospitalization (OR = 0.96; 95% CI: 0.87-1.06; <i>p</i> = 0.38; <i>I</i> ² = 89%). Both diuretics had a significant effect on weight change: torsemide (mean difference 2.36; 95% CI: 0.5-4.22; <i>p</i> = 0.01; <i>I</i> ² = 0.0%) and furosemide (mean difference 2.48; 95% CI: 0.81-4.15; <i>p</i> = 0.00; <i>I</i> ² = 0.0%). There was no significant difference in weight change between the two diuretics (mean difference -0.15; 95% CI: -0.82-0.52; <i>p</i> = 0.66; <i>I</i> ² = 94%).</p><p><strong>Conclusions: </strong>Furosemide and torsemide have similar impacts on mortality, hospitalization due to heart failure, and weight change in patients with congestive heart failure.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e45-e52"},"PeriodicalIF":0.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life-saving but limb-threatening: vasopressor-induced acral ischaemia and necrosis - two cases and review of the literature.","authors":"Vasileios Leivaditis, Francesk Mulita, Konstantinos Nikolakopoulos, Chrysa Andrikopoulou, Konstantinos Tasios, Elias Liolis, Andreas Antzoulas, Panagiotis Antzoulas, Dimitrios Litsas, Panagiotis Dimitrios Papadopoulos, George Theofanis, Ioannis Boucharas, Ioannis Panagiotopoulos, Tamas Büki, Manfred Dahm, Spyros Papadoulas","doi":"10.5114/amsad/216338","DOIUrl":"10.5114/amsad/216338","url":null,"abstract":"<p><p>Acral ischaemia and necrosis are rare but severe complications of high-dose or prolonged vasopressor therapy in critically ill patients. Although these agents are life-saving in distributive shock, intense α-adrenergic vasoconstriction, microcirculatory failure, and coagulopathy can converge to cause irreversible digital or limb necrosis, often requiring amputation and sometimes leading to medicolegal disputes. We report two cases of vasopressor-associated acral necrosis. These cases illustrate the multifactorial pathogenesis of vasopressor-induced acral necrosis, in which profound vasoconstriction, endothelial injury, microthrombosis, and the severity of underlying shock lead to distal tissue loss despite intact large-vessel pulses. Consequences include prolonged hospitalisation, the need for staged surgical or reconstructive procedures, long-term functional deficits, and substantial psychosocial burden. The dramatic nature of limb loss after life-saving therapy frequently triggers medicolegal scrutiny regarding dosing, monitoring, and documentation. Awareness of this uncommon but devastating complication is essential.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e38-e44"},"PeriodicalIF":0.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148220692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic role of low-volume plasma exchange in modulating lipopolysaccharides-binding protein and inflammatory pathways in metabolic syndrome.","authors":"Vjeroslava Slavic, Tanja Antunovic, Danijela Randjelovic, Nevena Terzic Stanic, Jelena Boljevic","doi":"10.5114/amsad/216575","DOIUrl":"10.5114/amsad/216575","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic syndrome (MetSy) is associated with chronic low-grade inflammation and metabolic dysfunction, contributing to increased cardiometabolic risk. Low-volume plasma exchange (LVPE) is an emerging extracorporeal therapy designed to reduce systemic inflammation by removing circulating pro-inflammatory mediators. This study evaluated the effects of LVPE on metabolic endotoxemia, inflammation, and mineral metabolism in individuals with MetSy.</p><p><strong>Material and methods: </strong>A total of 48 adults with MetSy were enrolled, including 33 men and 15 women, with an average age of 50 years (men: 51 years; women: 48 years). All participants met established diagnostic criteria for MetSy. Each underwent four LVPE cycles using nanoporous membranes designed to selectively remove pro-inflammatory mediators while preserving essential plasma components. Biomarkers of systemic inflammation (CRP, hsCRP), endotoxemia (LBP, zonulin), and mineral metabolism (zinc, magnesium, iron) were measured before and after treatment.</p><p><strong>Results: </strong>LVPE significantly reduced CRP levels (<i>p</i> < 0.020), demonstrating attenuation of systemic inflammation. A downward trend in hsCRP was observed (<i>p</i> < 0.050), though without reaching statistical significance. LVPE did not significantly affect endotoxemia markers (LBP, zonulin) or IL-6 (all <i>p</i> > 0.05). A significant post-treatment increase in zinc levels was detected (<i>p</i> < 0.009), while magnesium and iron remained unchanged (<i>p</i> > 0.05). A significant correlation between LBP and CRP after treatment (<i>p</i> < 0.027) suggests that LVPE may modulate systemic inflammation through immune regulatory pathways rather than by directly influencing endotoxemia.</p><p><strong>Conclusions: </strong>Four cycles of LVPE effectively reduced low-grade inflammation, as indicated by decreased CRP levels, supporting its potential role as a therapeutic approach in managing inflammation in MetSy. Its effects on endotoxemia and gut permeability remain inconclusive, underscoring the need for additional research to clarify long-term and mechanistic outcomes.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e17-e23"},"PeriodicalIF":0.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid ratios as early screening markers of dyslipidemia in normal-BMI university students: a cross-sectional epidemiologic study.","authors":"Samah Alfahl, Walaa Mohammedsaeed, Abdullah Alamri, Amira Elmihy, Fahad Almohammadi, Roaa Alhejli, Rami Aljohani","doi":"10.5114/amsad/215849","DOIUrl":"10.5114/amsad/215849","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to determine the prevalence of dyslipidemia and to assess the predictive performance of lipid ratios, specifically the Atherogenic Index of Plasma (AIP) and the total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) (TC/HDL) ratio, compared to body mass index (BMI) in identifying dyslipidemia among non-obese male university students.</p><p><strong>Material and methods: </strong>A cross-sectional study was conducted among 150 male students aged 20-30 years at a Saudi Arabian university. Participants underwent fasting lipid profiling, anthropometric measurements, and assessments of lifestyle behaviors including diet, physical activity, and smoking. Dyslipidemia was defined based on the NCEP-ATP III criteria. Predictive accuracy of AIP, TC/HDL ratio, and BMI was evaluated using receiver operating characteristic (ROC) curve analysis and logistic regression.</p><p><strong>Results: </strong>Dyslipidemia was detected in 60.7% of participants, despite a mean BMI of 25.3 ±4.0 kg/m², indicating that a substantial proportion of metabolically at-risk individuals were not obese. Unhealthy lifestyle behaviors were associated with an approximately eightfold increase in the odds of dyslipidemia (<i>p</i> < 0.001). Both AIP (AUC = 0.865) and TC/HDL ratio (AUC = 0.873) demonstrated significantly superior predictive performance compared with BMI (AUC = 0.570). More than 63% of students were classified as high-risk based on AIP levels. Cluster analysis revealed a distinct LDL-TG dominant phenotype strongly associated with unhealthy lifestyle factors.</p><p><strong>Conclusions: </strong>Lipid ratios, particularly AIP and TC/HDL, outperformed BMI in predicting early dyslipidemia among non-obese young adults. Incorporating these indices into routine screening could facilitate earlier detection of cardiovascular risk in university and preventive health settings, emphasizing the importance of targeted lifestyle interventions.</p>","PeriodicalId":516556,"journal":{"name":"Archives of medical sciences. Atherosclerotic diseases","volume":"11 ","pages":"e5-e11"},"PeriodicalIF":0.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}